Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2‑positive cancers.
Authors
Martin Wermke
University Hospital Carl-Gustav-Carus, Dresden, Germany
Martin Wermke, Juergen Alt, John S. Kauh, Jonathan Back, Yacine Salhi, Venkateshwar Reddy, Eliel Bayever, Sebastian Ochsenreither
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Modulating Innate Immunity
Clinical Trial Registration Number
NCT02829372
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 69)
DOI
10.1200/JCO.2018.36.5_suppl.69
Abstract #
69
Poster Bd #
E5
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Single-cell cytokine profiling of tumor-infiltrating T cells to measure patient responses to anti-PD-1 therapy.
First Author: Sean Mackay
Poster
2020 ASCO Virtual Scientific Program
Eradication of medulloblastoma by NKG2D-specific CAR T-cells.
First Author: Hong-jiu Dai
Poster
2015 Gastrointestinal Cancers Symposium
T-cell redirected killing and cure of pancreatic and gastric cancer xenografts by targeting Trop-2.
First Author: David M. Goldenberg
Poster
2024 ASCO Annual Meeting
Dynamics of circulating cytokines and chemokines during and after tumor-infiltrating lymphocyte cell therapy with lifileucel in advanced melanoma patients.
First Author: Rongsu Qi